Global Golidocitinib Market Growth 2026-2032
The global Golidocitinib market size is predicted to grow from US$ 221 million in 2025 to US$ 970 million in 2032; it is expected to grow at a CAGR of 17.3% from 2026 to 2032.
Golidocitinib is a highly selective, orally bioavailable small-molecule JAK1 inhibitor, mainly used for the treatment of hematologic malignancies such as relapsed or refractory peripheral T-cell lymphoma. The drug specifically inhibits the JAK-STAT signaling pathway, blocking abnormal cell proliferation and inflammatory signal transduction, thereby suppressing tumor cell growth and delaying disease progression. As a new generation of targeted antineoplastic agents, golidocitinib features high target selectivity, low off-target effects, and controllable clinical safety. It provides a new therapeutic option for patients with relapsed and refractory lymphoma and represents one of the important innovative targeted drugs in the field of lymphoma.In 2025, global Golidocitinib production reached approximately 110,000?120,000 bottles.
As a globally first-in-class highly selective JAK1 inhibitor, golidocitinib has precisely filled the long-standing clinical gap in the treatment of relapsed and refractory peripheral T-cell lymphoma since its launch. With its unique mechanism of action and significant survival benefits, it has rapidly established a core position in the targeted market. Relying on its globally exclusive target, breakthrough therapeutic efficacy, and highest-level recommendations from authoritative clinical guidelines, the drug has built strong market competitiveness and technical barriers. Following its inclusion in medical insurance, its accessibility has been greatly improved, market penetration and patient coverage continue to expand, and the commercialization process has accelerated significantly. In terms of competitive landscape, it enjoys obvious first-mover advantages, while similar competitors remain in late-stage clinical development, making it difficult to challenge its dominant position in the short term. Meanwhile, with the active expansion of multiple indications such as first-line treatment, combination therapy, and other T-cell lymphoma subtypes, golidocitinib is extending from second-line salvage therapy to full-course disease management, continuously unlocking its market potential and product life cycle. In the future, it is expected to further consolidate its benchmark value in the global targeted therapy for hematologic malignancies through its differentiated advantages and international layout.
LP Information, Inc. (LPI) ' newest research report, the ?Golidocitinib Industry Forecast? looks at past sales and reviews total world Golidocitinib sales in 2025, providing a comprehensive analysis by region and market sector of projected Golidocitinib sales for 2026 through 2032. With Golidocitinib sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Golidocitinib industry.
This Insight Report provides a comprehensive analysis of the global Golidocitinib landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Golidocitinib portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Golidocitinib market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Golidocitinib and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Golidocitinib.
This report presents a comprehensive overview, market shares, and growth opportunities of Golidocitinib market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Golidocitinib market?
What factors are driving Golidocitinib market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Golidocitinib market opportunities vary by end market size?
How does Golidocitinib break out by Type, by Application?
Golidocitinib is a highly selective, orally bioavailable small-molecule JAK1 inhibitor, mainly used for the treatment of hematologic malignancies such as relapsed or refractory peripheral T-cell lymphoma. The drug specifically inhibits the JAK-STAT signaling pathway, blocking abnormal cell proliferation and inflammatory signal transduction, thereby suppressing tumor cell growth and delaying disease progression. As a new generation of targeted antineoplastic agents, golidocitinib features high target selectivity, low off-target effects, and controllable clinical safety. It provides a new therapeutic option for patients with relapsed and refractory lymphoma and represents one of the important innovative targeted drugs in the field of lymphoma.In 2025, global Golidocitinib production reached approximately 110,000?120,000 bottles.
As a globally first-in-class highly selective JAK1 inhibitor, golidocitinib has precisely filled the long-standing clinical gap in the treatment of relapsed and refractory peripheral T-cell lymphoma since its launch. With its unique mechanism of action and significant survival benefits, it has rapidly established a core position in the targeted market. Relying on its globally exclusive target, breakthrough therapeutic efficacy, and highest-level recommendations from authoritative clinical guidelines, the drug has built strong market competitiveness and technical barriers. Following its inclusion in medical insurance, its accessibility has been greatly improved, market penetration and patient coverage continue to expand, and the commercialization process has accelerated significantly. In terms of competitive landscape, it enjoys obvious first-mover advantages, while similar competitors remain in late-stage clinical development, making it difficult to challenge its dominant position in the short term. Meanwhile, with the active expansion of multiple indications such as first-line treatment, combination therapy, and other T-cell lymphoma subtypes, golidocitinib is extending from second-line salvage therapy to full-course disease management, continuously unlocking its market potential and product life cycle. In the future, it is expected to further consolidate its benchmark value in the global targeted therapy for hematologic malignancies through its differentiated advantages and international layout.
LP Information, Inc. (LPI) ' newest research report, the ?Golidocitinib Industry Forecast? looks at past sales and reviews total world Golidocitinib sales in 2025, providing a comprehensive analysis by region and market sector of projected Golidocitinib sales for 2026 through 2032. With Golidocitinib sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Golidocitinib industry.
This Insight Report provides a comprehensive analysis of the global Golidocitinib landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Golidocitinib portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Golidocitinib market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Golidocitinib and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Golidocitinib.
This report presents a comprehensive overview, market shares, and growth opportunities of Golidocitinib market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- 150 mg
- 100 mg
- Relapsed Or Refractory Peripheral T-Cell Lymphoma
- Other T-Cell Lymphoma Subtypes
- Hematologic Malignancies
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Dizhe (Jiangsu) Pharmaceutical
What is the 10-year outlook for the global Golidocitinib market?
What factors are driving Golidocitinib market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Golidocitinib market opportunities vary by end market size?
How does Golidocitinib break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Golidocitinib Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Golidocitinib by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Golidocitinib by Country/Region, 2021, 2025 & 2032
2.2 Golidocitinib Segment by Type
2.2.1 150 mg
2.2.2 100 mg
2.2.3 Golidocitinib Sales by Type
2.2.3.1 Global Golidocitinib Sales Market Share by Type (2021-2026)
2.2.3.2 Global Golidocitinib Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Golidocitinib Sale Price by Type (2021-2026)
2.3 Golidocitinib Segment by Application
2.3.1 Relapsed Or Refractory Peripheral T-Cell Lymphoma
2.3.2 Other T-Cell Lymphoma Subtypes
2.3.3 Hematologic Malignancies
2.3.4 Others
2.3.5 Golidocitinib Sales by Application
2.3.5.1 Global Golidocitinib Sale Market Share by Application (2021-2026)
2.3.5.2 Global Golidocitinib Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Golidocitinib Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Golidocitinib Breakdown Data by Company
3.1.1 Global Golidocitinib Annual Sales by Company (2021-2026)
3.1.2 Global Golidocitinib Sales Market Share by Company (2021-2026)
3.2 Global Golidocitinib Annual Revenue by Company (2021-2026)
3.2.1 Global Golidocitinib Revenue by Company (2021-2026)
3.2.2 Global Golidocitinib Revenue Market Share by Company (2021-2026)
3.3 Global Golidocitinib Sale Price by Company
3.4 Key Manufacturers Golidocitinib Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Golidocitinib Product Location Distribution
3.4.2 Players Golidocitinib Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR GOLIDOCITINIB BY GEOGRAPHIC REGION
4.1 World Historic Golidocitinib Market Size by Geographic Region (2021-2026)
4.1.1 Global Golidocitinib Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Golidocitinib Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Golidocitinib Market Size by Country/Region (2021-2026)
4.2.1 Global Golidocitinib Annual Sales by Country/Region (2021-2026)
4.2.2 Global Golidocitinib Annual Revenue by Country/Region (2021-2026)
4.3 Americas Golidocitinib Sales Growth
4.4 APAC Golidocitinib Sales Growth
4.5 Europe Golidocitinib Sales Growth
4.6 Middle East & Africa Golidocitinib Sales Growth
5 AMERICAS
5.1 Americas Golidocitinib Sales by Country
5.1.1 Americas Golidocitinib Sales by Country (2021-2026)
5.1.2 Americas Golidocitinib Revenue by Country (2021-2026)
5.2 Americas Golidocitinib Sales by Type (2021-2026)
5.3 Americas Golidocitinib Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Golidocitinib Sales by Region
6.1.1 APAC Golidocitinib Sales by Region (2021-2026)
6.1.2 APAC Golidocitinib Revenue by Region (2021-2026)
6.2 APAC Golidocitinib Sales by Type (2021-2026)
6.3 APAC Golidocitinib Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Golidocitinib by Country
7.1.1 Europe Golidocitinib Sales by Country (2021-2026)
7.1.2 Europe Golidocitinib Revenue by Country (2021-2026)
7.2 Europe Golidocitinib Sales by Type (2021-2026)
7.3 Europe Golidocitinib Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Golidocitinib by Country
8.1.1 Middle East & Africa Golidocitinib Sales by Country (2021-2026)
8.1.2 Middle East & Africa Golidocitinib Revenue by Country (2021-2026)
8.2 Middle East & Africa Golidocitinib Sales by Type (2021-2026)
8.3 Middle East & Africa Golidocitinib Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Golidocitinib
10.3 Manufacturing Process Analysis of Golidocitinib
10.4 Industry Chain Structure of Golidocitinib
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Golidocitinib Distributors
11.3 Golidocitinib Customer
12 WORLD FORECAST REVIEW FOR GOLIDOCITINIB BY GEOGRAPHIC REGION
12.1 Global Golidocitinib Market Size Forecast by Region
12.1.1 Global Golidocitinib Forecast by Region (2027-2032)
12.1.2 Global Golidocitinib Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Golidocitinib Forecast by Type (2027-2032)
12.7 Global Golidocitinib Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Dizhe (Jiangsu) Pharmaceutical
13.1.1 Dizhe (Jiangsu) Pharmaceutical Company Information
13.1.2 Dizhe (Jiangsu) Pharmaceutical Golidocitinib Product Portfolios and Specifications
13.1.3 Dizhe (Jiangsu) Pharmaceutical Golidocitinib Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Dizhe (Jiangsu) Pharmaceutical Main Business Overview
13.1.5 Dizhe (Jiangsu) Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Golidocitinib Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Golidocitinib by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Golidocitinib by Country/Region, 2021, 2025 & 2032
2.2 Golidocitinib Segment by Type
2.2.1 150 mg
2.2.2 100 mg
2.2.3 Golidocitinib Sales by Type
2.2.3.1 Global Golidocitinib Sales Market Share by Type (2021-2026)
2.2.3.2 Global Golidocitinib Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Golidocitinib Sale Price by Type (2021-2026)
2.3 Golidocitinib Segment by Application
2.3.1 Relapsed Or Refractory Peripheral T-Cell Lymphoma
2.3.2 Other T-Cell Lymphoma Subtypes
2.3.3 Hematologic Malignancies
2.3.4 Others
2.3.5 Golidocitinib Sales by Application
2.3.5.1 Global Golidocitinib Sale Market Share by Application (2021-2026)
2.3.5.2 Global Golidocitinib Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Golidocitinib Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Golidocitinib Breakdown Data by Company
3.1.1 Global Golidocitinib Annual Sales by Company (2021-2026)
3.1.2 Global Golidocitinib Sales Market Share by Company (2021-2026)
3.2 Global Golidocitinib Annual Revenue by Company (2021-2026)
3.2.1 Global Golidocitinib Revenue by Company (2021-2026)
3.2.2 Global Golidocitinib Revenue Market Share by Company (2021-2026)
3.3 Global Golidocitinib Sale Price by Company
3.4 Key Manufacturers Golidocitinib Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Golidocitinib Product Location Distribution
3.4.2 Players Golidocitinib Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR GOLIDOCITINIB BY GEOGRAPHIC REGION
4.1 World Historic Golidocitinib Market Size by Geographic Region (2021-2026)
4.1.1 Global Golidocitinib Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Golidocitinib Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Golidocitinib Market Size by Country/Region (2021-2026)
4.2.1 Global Golidocitinib Annual Sales by Country/Region (2021-2026)
4.2.2 Global Golidocitinib Annual Revenue by Country/Region (2021-2026)
4.3 Americas Golidocitinib Sales Growth
4.4 APAC Golidocitinib Sales Growth
4.5 Europe Golidocitinib Sales Growth
4.6 Middle East & Africa Golidocitinib Sales Growth
5 AMERICAS
5.1 Americas Golidocitinib Sales by Country
5.1.1 Americas Golidocitinib Sales by Country (2021-2026)
5.1.2 Americas Golidocitinib Revenue by Country (2021-2026)
5.2 Americas Golidocitinib Sales by Type (2021-2026)
5.3 Americas Golidocitinib Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Golidocitinib Sales by Region
6.1.1 APAC Golidocitinib Sales by Region (2021-2026)
6.1.2 APAC Golidocitinib Revenue by Region (2021-2026)
6.2 APAC Golidocitinib Sales by Type (2021-2026)
6.3 APAC Golidocitinib Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Golidocitinib by Country
7.1.1 Europe Golidocitinib Sales by Country (2021-2026)
7.1.2 Europe Golidocitinib Revenue by Country (2021-2026)
7.2 Europe Golidocitinib Sales by Type (2021-2026)
7.3 Europe Golidocitinib Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Golidocitinib by Country
8.1.1 Middle East & Africa Golidocitinib Sales by Country (2021-2026)
8.1.2 Middle East & Africa Golidocitinib Revenue by Country (2021-2026)
8.2 Middle East & Africa Golidocitinib Sales by Type (2021-2026)
8.3 Middle East & Africa Golidocitinib Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Golidocitinib
10.3 Manufacturing Process Analysis of Golidocitinib
10.4 Industry Chain Structure of Golidocitinib
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Golidocitinib Distributors
11.3 Golidocitinib Customer
12 WORLD FORECAST REVIEW FOR GOLIDOCITINIB BY GEOGRAPHIC REGION
12.1 Global Golidocitinib Market Size Forecast by Region
12.1.1 Global Golidocitinib Forecast by Region (2027-2032)
12.1.2 Global Golidocitinib Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Golidocitinib Forecast by Type (2027-2032)
12.7 Global Golidocitinib Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Dizhe (Jiangsu) Pharmaceutical
13.1.1 Dizhe (Jiangsu) Pharmaceutical Company Information
13.1.2 Dizhe (Jiangsu) Pharmaceutical Golidocitinib Product Portfolios and Specifications
13.1.3 Dizhe (Jiangsu) Pharmaceutical Golidocitinib Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Dizhe (Jiangsu) Pharmaceutical Main Business Overview
13.1.5 Dizhe (Jiangsu) Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Golidocitinib Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Golidocitinib Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 150 mg
Table 4. Major Players of 100 mg
Table 5. Global Golidocitinib Sales by Type (2021-2026) & (Units)
Table 6. Global Golidocitinib Sales Market Share by Type (2021-2026)
Table 7. Global Golidocitinib Revenue by Type (2021-2026) & ($ million)
Table 8. Global Golidocitinib Revenue Market Share by Type (2021-2026)
Table 9. Global Golidocitinib Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of Combination With Chemotherapy
Table 11. Major Players of Combination With Targeted Therapy
Table 12. Global Golidocitinib Sale by Application (2021-2026) & (Units)
Table 13. Global Golidocitinib Sale Market Share by Application (2021-2026)
Table 14. Global Golidocitinib Revenue by Application (2021-2026) & ($ million)
Table 15. Global Golidocitinib Revenue Market Share by Application (2021-2026)
Table 16. Global Golidocitinib Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Golidocitinib Sales by Company (2021-2026) & (Units)
Table 18. Global Golidocitinib Sales Market Share by Company (2021-2026)
Table 19. Global Golidocitinib Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Golidocitinib Revenue Market Share by Company (2021-2026)
Table 21. Global Golidocitinib Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Golidocitinib Producing Area Distribution and Sales Area
Table 23. Players Golidocitinib Products Offered
Table 24. Golidocitinib Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Golidocitinib Sales by Geographic Region (2021-2026) & (Units)
Table 28. Global Golidocitinib Sales Market Share Geographic Region (2021-2026)
Table 29. Global Golidocitinib Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Golidocitinib Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Golidocitinib Sales by Country/Region (2021-2026) & (Units)
Table 32. Global Golidocitinib Sales Market Share by Country/Region (2021-2026)
Table 33. Global Golidocitinib Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Golidocitinib Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Golidocitinib Sales by Country (2021-2026) & (Units)
Table 36. Americas Golidocitinib Sales Market Share by Country (2021-2026)
Table 37. Americas Golidocitinib Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Golidocitinib Sales by Type (2021-2026) & (Units)
Table 39. Americas Golidocitinib Sales by Application (2021-2026) & (Units)
Table 40. APAC Golidocitinib Sales by Region (2021-2026) & (Units)
Table 41. APAC Golidocitinib Sales Market Share by Region (2021-2026)
Table 42. APAC Golidocitinib Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Golidocitinib Sales by Type (2021-2026) & (Units)
Table 44. APAC Golidocitinib Sales by Application (2021-2026) & (Units)
Table 45. Europe Golidocitinib Sales by Country (2021-2026) & (Units)
Table 46. Europe Golidocitinib Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Golidocitinib Sales by Type (2021-2026) & (Units)
Table 48. Europe Golidocitinib Sales by Application (2021-2026) & (Units)
Table 49. Middle East & Africa Golidocitinib Sales by Country (2021-2026) & (Units)
Table 50. Middle East & Africa Golidocitinib Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Golidocitinib Sales by Type (2021-2026) & (Units)
Table 52. Middle East & Africa Golidocitinib Sales by Application (2021-2026) & (Units)
Table 53. Key Market Drivers & Growth Opportunities of Golidocitinib
Table 54. Key Market Challenges & Risks of Golidocitinib
Table 55. Key Industry Trends of Golidocitinib
Table 56. Golidocitinib Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Golidocitinib Distributors List
Table 59. Golidocitinib Customer List
Table 60. Global Golidocitinib Sales Forecast by Region (2027-2032) & (Units)
Table 61. Global Golidocitinib Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Golidocitinib Sales Forecast by Country (2027-2032) & (Units)
Table 63. Americas Golidocitinib Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Golidocitinib Sales Forecast by Region (2027-2032) & (Units)
Table 65. APAC Golidocitinib Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Golidocitinib Sales Forecast by Country (2027-2032) & (Units)
Table 67. Europe Golidocitinib Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Golidocitinib Sales Forecast by Country (2027-2032) & (Units)
Table 69. Middle East & Africa Golidocitinib Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Golidocitinib Sales Forecast by Type (2027-2032) & (Units)
Table 71. Global Golidocitinib Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Golidocitinib Sales Forecast by Application (2027-2032) & (Units)
Table 73. Global Golidocitinib Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Dizhe (Jiangsu) Pharmaceutical Basic Information, Golidocitinib Manufacturing Base, Sales Area and Its Competitors
Table 75. Dizhe (Jiangsu) Pharmaceutical Golidocitinib Product Portfolios and Specifications
Table 76. Dizhe (Jiangsu) Pharmaceutical Golidocitinib Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Dizhe (Jiangsu) Pharmaceutical Main Business
Table 78. Dizhe (Jiangsu) Pharmaceutical Latest Developments
Table 1. Golidocitinib Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Golidocitinib Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 150 mg
Table 4. Major Players of 100 mg
Table 5. Global Golidocitinib Sales by Type (2021-2026) & (Units)
Table 6. Global Golidocitinib Sales Market Share by Type (2021-2026)
Table 7. Global Golidocitinib Revenue by Type (2021-2026) & ($ million)
Table 8. Global Golidocitinib Revenue Market Share by Type (2021-2026)
Table 9. Global Golidocitinib Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of Combination With Chemotherapy
Table 11. Major Players of Combination With Targeted Therapy
Table 12. Global Golidocitinib Sale by Application (2021-2026) & (Units)
Table 13. Global Golidocitinib Sale Market Share by Application (2021-2026)
Table 14. Global Golidocitinib Revenue by Application (2021-2026) & ($ million)
Table 15. Global Golidocitinib Revenue Market Share by Application (2021-2026)
Table 16. Global Golidocitinib Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Golidocitinib Sales by Company (2021-2026) & (Units)
Table 18. Global Golidocitinib Sales Market Share by Company (2021-2026)
Table 19. Global Golidocitinib Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Golidocitinib Revenue Market Share by Company (2021-2026)
Table 21. Global Golidocitinib Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Golidocitinib Producing Area Distribution and Sales Area
Table 23. Players Golidocitinib Products Offered
Table 24. Golidocitinib Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Golidocitinib Sales by Geographic Region (2021-2026) & (Units)
Table 28. Global Golidocitinib Sales Market Share Geographic Region (2021-2026)
Table 29. Global Golidocitinib Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Golidocitinib Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Golidocitinib Sales by Country/Region (2021-2026) & (Units)
Table 32. Global Golidocitinib Sales Market Share by Country/Region (2021-2026)
Table 33. Global Golidocitinib Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Golidocitinib Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Golidocitinib Sales by Country (2021-2026) & (Units)
Table 36. Americas Golidocitinib Sales Market Share by Country (2021-2026)
Table 37. Americas Golidocitinib Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Golidocitinib Sales by Type (2021-2026) & (Units)
Table 39. Americas Golidocitinib Sales by Application (2021-2026) & (Units)
Table 40. APAC Golidocitinib Sales by Region (2021-2026) & (Units)
Table 41. APAC Golidocitinib Sales Market Share by Region (2021-2026)
Table 42. APAC Golidocitinib Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Golidocitinib Sales by Type (2021-2026) & (Units)
Table 44. APAC Golidocitinib Sales by Application (2021-2026) & (Units)
Table 45. Europe Golidocitinib Sales by Country (2021-2026) & (Units)
Table 46. Europe Golidocitinib Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Golidocitinib Sales by Type (2021-2026) & (Units)
Table 48. Europe Golidocitinib Sales by Application (2021-2026) & (Units)
Table 49. Middle East & Africa Golidocitinib Sales by Country (2021-2026) & (Units)
Table 50. Middle East & Africa Golidocitinib Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Golidocitinib Sales by Type (2021-2026) & (Units)
Table 52. Middle East & Africa Golidocitinib Sales by Application (2021-2026) & (Units)
Table 53. Key Market Drivers & Growth Opportunities of Golidocitinib
Table 54. Key Market Challenges & Risks of Golidocitinib
Table 55. Key Industry Trends of Golidocitinib
Table 56. Golidocitinib Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Golidocitinib Distributors List
Table 59. Golidocitinib Customer List
Table 60. Global Golidocitinib Sales Forecast by Region (2027-2032) & (Units)
Table 61. Global Golidocitinib Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Golidocitinib Sales Forecast by Country (2027-2032) & (Units)
Table 63. Americas Golidocitinib Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Golidocitinib Sales Forecast by Region (2027-2032) & (Units)
Table 65. APAC Golidocitinib Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Golidocitinib Sales Forecast by Country (2027-2032) & (Units)
Table 67. Europe Golidocitinib Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Golidocitinib Sales Forecast by Country (2027-2032) & (Units)
Table 69. Middle East & Africa Golidocitinib Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Golidocitinib Sales Forecast by Type (2027-2032) & (Units)
Table 71. Global Golidocitinib Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Golidocitinib Sales Forecast by Application (2027-2032) & (Units)
Table 73. Global Golidocitinib Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Dizhe (Jiangsu) Pharmaceutical Basic Information, Golidocitinib Manufacturing Base, Sales Area and Its Competitors
Table 75. Dizhe (Jiangsu) Pharmaceutical Golidocitinib Product Portfolios and Specifications
Table 76. Dizhe (Jiangsu) Pharmaceutical Golidocitinib Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Dizhe (Jiangsu) Pharmaceutical Main Business
Table 78. Dizhe (Jiangsu) Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Picture of Golidocitinib
Figure 2. Golidocitinib Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Golidocitinib Sales Growth Rate 2021-2032 (Units)
Figure 7. Global Golidocitinib Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Golidocitinib Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Golidocitinib Sales Market Share by Country/Region (2025)
Figure 10. Golidocitinib Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 150 mg
Figure 12. Product Picture of 100 mg
Figure 13. Global Golidocitinib Sales Market Share by Type in 2026
Figure 14. Global Golidocitinib Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Combination With Chemotherapy
Figure 16. Product Picture of Combination With Targeted Therapy
Figure 17. Golidocitinib Consumed in Relapsed Or Refractory Peripheral T-Cell Lymphoma
Figure 18. Global Golidocitinib Market: Relapsed Or Refractory Peripheral T-Cell Lymphoma (2021-2026) & (Units)
Figure 19. Golidocitinib Consumed in Other T-Cell Lymphoma Subtypes
Figure 20. Global Golidocitinib Market: Other T-Cell Lymphoma Subtypes (2021-2026) & (Units)
Figure 21. Golidocitinib Consumed in Hematologic Malignancies
Figure 22. Global Golidocitinib Market: Hematologic Malignancies (2021-2026) & (Units)
Figure 23. Golidocitinib Consumed in Others
Figure 24. Global Golidocitinib Market: Others (2021-2026) & (Units)
Figure 25. Global Golidocitinib Sale Market Share by Application (2025)
Figure 26. Global Golidocitinib Revenue Market Share by Application in 2025
Figure 27. Golidocitinib Sales by Company in 2025 (Units)
Figure 28. Global Golidocitinib Sales Market Share by Company in 2025
Figure 29. Golidocitinib Revenue by Company in 2025 ($ millions)
Figure 30. Global Golidocitinib Revenue Market Share by Company in 2025
Figure 31. Global Golidocitinib Sales Market Share by Geographic Region (2021-2026)
Figure 32. Global Golidocitinib Revenue Market Share by Geographic Region in 2025
Figure 33. Americas Golidocitinib Sales 2021-2026 (Units)
Figure 34. Americas Golidocitinib Revenue 2021-2026 ($ millions)
Figure 35. APAC Golidocitinib Sales 2021-2026 (Units)
Figure 36. APAC Golidocitinib Revenue 2021-2026 ($ millions)
Figure 37. Europe Golidocitinib Sales 2021-2026 (Units)
Figure 38. Europe Golidocitinib Revenue 2021-2026 ($ millions)
Figure 39. Middle East & Africa Golidocitinib Sales 2021-2026 (Units)
Figure 40. Middle East & Africa Golidocitinib Revenue 2021-2026 ($ millions)
Figure 41. Americas Golidocitinib Sales Market Share by Country in 2025
Figure 42. Americas Golidocitinib Revenue Market Share by Country (2021-2026)
Figure 43. Americas Golidocitinib Sales Market Share by Type (2021-2026)
Figure 44. Americas Golidocitinib Sales Market Share by Application (2021-2026)
Figure 45. United States Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 46. Canada Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 47. Mexico Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 48. Brazil Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 49. APAC Golidocitinib Sales Market Share by Region in 2025
Figure 50. APAC Golidocitinib Revenue Market Share by Region (2021-2026)
Figure 51. APAC Golidocitinib Sales Market Share by Type (2021-2026)
Figure 52. APAC Golidocitinib Sales Market Share by Application (2021-2026)
Figure 53. China Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 54. Japan Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 55. South Korea Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 56. Southeast Asia Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 57. India Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 58. Australia Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 59. China Taiwan Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 60. Europe Golidocitinib Sales Market Share by Country in 2025
Figure 61. Europe Golidocitinib Revenue Market Share by Country (2021-2026)
Figure 62. Europe Golidocitinib Sales Market Share by Type (2021-2026)
Figure 63. Europe Golidocitinib Sales Market Share by Application (2021-2026)
Figure 64. Germany Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 65. France Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 66. UK Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 67. Italy Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 68. Russia Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 69. Middle East & Africa Golidocitinib Sales Market Share by Country (2021-2026)
Figure 70. Middle East & Africa Golidocitinib Sales Market Share by Type (2021-2026)
Figure 71. Middle East & Africa Golidocitinib Sales Market Share by Application (2021-2026)
Figure 72. Egypt Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 73. South Africa Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 74. Israel Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 75. Turkey Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 76. GCC Countries Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Golidocitinib in 2026
Figure 78. Manufacturing Process Analysis of Golidocitinib
Figure 79. Industry Chain Structure of Golidocitinib
Figure 80. Channels of Distribution
Figure 81. Global Golidocitinib Sales Market Forecast by Region (2027-2032)
Figure 82. Global Golidocitinib Revenue Market Share Forecast by Region (2027-2032)
Figure 83. Global Golidocitinib Sales Market Share Forecast by Type (2027-2032)
Figure 84. Global Golidocitinib Revenue Market Share Forecast by Type (2027-2032)
Figure 85. Global Golidocitinib Sales Market Share Forecast by Application (2027-2032)
Figure 86. Global Golidocitinib Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Golidocitinib
Figure 2. Golidocitinib Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Golidocitinib Sales Growth Rate 2021-2032 (Units)
Figure 7. Global Golidocitinib Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Golidocitinib Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Golidocitinib Sales Market Share by Country/Region (2025)
Figure 10. Golidocitinib Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 150 mg
Figure 12. Product Picture of 100 mg
Figure 13. Global Golidocitinib Sales Market Share by Type in 2026
Figure 14. Global Golidocitinib Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Combination With Chemotherapy
Figure 16. Product Picture of Combination With Targeted Therapy
Figure 17. Golidocitinib Consumed in Relapsed Or Refractory Peripheral T-Cell Lymphoma
Figure 18. Global Golidocitinib Market: Relapsed Or Refractory Peripheral T-Cell Lymphoma (2021-2026) & (Units)
Figure 19. Golidocitinib Consumed in Other T-Cell Lymphoma Subtypes
Figure 20. Global Golidocitinib Market: Other T-Cell Lymphoma Subtypes (2021-2026) & (Units)
Figure 21. Golidocitinib Consumed in Hematologic Malignancies
Figure 22. Global Golidocitinib Market: Hematologic Malignancies (2021-2026) & (Units)
Figure 23. Golidocitinib Consumed in Others
Figure 24. Global Golidocitinib Market: Others (2021-2026) & (Units)
Figure 25. Global Golidocitinib Sale Market Share by Application (2025)
Figure 26. Global Golidocitinib Revenue Market Share by Application in 2025
Figure 27. Golidocitinib Sales by Company in 2025 (Units)
Figure 28. Global Golidocitinib Sales Market Share by Company in 2025
Figure 29. Golidocitinib Revenue by Company in 2025 ($ millions)
Figure 30. Global Golidocitinib Revenue Market Share by Company in 2025
Figure 31. Global Golidocitinib Sales Market Share by Geographic Region (2021-2026)
Figure 32. Global Golidocitinib Revenue Market Share by Geographic Region in 2025
Figure 33. Americas Golidocitinib Sales 2021-2026 (Units)
Figure 34. Americas Golidocitinib Revenue 2021-2026 ($ millions)
Figure 35. APAC Golidocitinib Sales 2021-2026 (Units)
Figure 36. APAC Golidocitinib Revenue 2021-2026 ($ millions)
Figure 37. Europe Golidocitinib Sales 2021-2026 (Units)
Figure 38. Europe Golidocitinib Revenue 2021-2026 ($ millions)
Figure 39. Middle East & Africa Golidocitinib Sales 2021-2026 (Units)
Figure 40. Middle East & Africa Golidocitinib Revenue 2021-2026 ($ millions)
Figure 41. Americas Golidocitinib Sales Market Share by Country in 2025
Figure 42. Americas Golidocitinib Revenue Market Share by Country (2021-2026)
Figure 43. Americas Golidocitinib Sales Market Share by Type (2021-2026)
Figure 44. Americas Golidocitinib Sales Market Share by Application (2021-2026)
Figure 45. United States Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 46. Canada Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 47. Mexico Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 48. Brazil Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 49. APAC Golidocitinib Sales Market Share by Region in 2025
Figure 50. APAC Golidocitinib Revenue Market Share by Region (2021-2026)
Figure 51. APAC Golidocitinib Sales Market Share by Type (2021-2026)
Figure 52. APAC Golidocitinib Sales Market Share by Application (2021-2026)
Figure 53. China Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 54. Japan Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 55. South Korea Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 56. Southeast Asia Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 57. India Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 58. Australia Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 59. China Taiwan Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 60. Europe Golidocitinib Sales Market Share by Country in 2025
Figure 61. Europe Golidocitinib Revenue Market Share by Country (2021-2026)
Figure 62. Europe Golidocitinib Sales Market Share by Type (2021-2026)
Figure 63. Europe Golidocitinib Sales Market Share by Application (2021-2026)
Figure 64. Germany Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 65. France Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 66. UK Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 67. Italy Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 68. Russia Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 69. Middle East & Africa Golidocitinib Sales Market Share by Country (2021-2026)
Figure 70. Middle East & Africa Golidocitinib Sales Market Share by Type (2021-2026)
Figure 71. Middle East & Africa Golidocitinib Sales Market Share by Application (2021-2026)
Figure 72. Egypt Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 73. South Africa Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 74. Israel Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 75. Turkey Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 76. GCC Countries Golidocitinib Revenue Growth 2021-2026 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Golidocitinib in 2026
Figure 78. Manufacturing Process Analysis of Golidocitinib
Figure 79. Industry Chain Structure of Golidocitinib
Figure 80. Channels of Distribution
Figure 81. Global Golidocitinib Sales Market Forecast by Region (2027-2032)
Figure 82. Global Golidocitinib Revenue Market Share Forecast by Region (2027-2032)
Figure 83. Global Golidocitinib Sales Market Share Forecast by Type (2027-2032)
Figure 84. Global Golidocitinib Revenue Market Share Forecast by Type (2027-2032)
Figure 85. Global Golidocitinib Sales Market Share Forecast by Application (2027-2032)
Figure 86. Global Golidocitinib Revenue Market Share Forecast by Application (2027-2032)
